Of the 5 patients with an ANC of < 1.5 × 109/L and ANC > 1.0 × 109/L, recovery from the neutropenia was rapid and allowed continued dosing, usually without the need for granulocyte-colony stimulating factor treatment, demonstrating that this dose and schedule was, in fact, tolerable. This evidence concerns the gene CSF3 and neutropenia.